Patents by Inventor Angela Krackhardt

Angela Krackhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Allorestricted peptide-specific T cells
    Patent number: 8633020
    Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: January 21, 2014
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt
    Inventors: Angela Krackhardt, Ingrid Schuster, Dirk Busch
  • ALLORESTRICTED PEPTIDE-SPECIFIC T CELLS
    Publication number: 20120269833
    Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.
    Type: Application
    Filed: July 9, 2012
    Publication date: October 25, 2012
    Inventors: Angela Krackhardt, Ingrid Schuster, Dirk Busch
  • Allorestricted peptide-specific T cells
    Patent number: 8217009
    Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: July 10, 2012
    Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt
    Inventors: Angela Krackhardt, Ingrid Schuster, Dirk Busch
  • HER2/NEU SPECIFIC T CELL RECEPTORS
    Publication number: 20110280894
    Abstract: The present invention is directed to T cell receptors (TCR) recognizing antigenic peptides derived from Her2/neu, in particular peptide 369, and being capable of inducing peptide specific killing of a target cell overexpressing HER2/neu. The present invention is further directed to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of HER2/neu. The present invention is further disclosing a method of generating antigen specific T cells.
    Type: Application
    Filed: July 31, 2009
    Publication date: November 17, 2011
    Inventors: Angela Krackhardt, Luise Weigand, Xiaoling Liang
  • ALLORESTRICTED PEPTIDE-SPECIFIC T CELLS
    Publication number: 20100055117
    Abstract: The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.
    Type: Application
    Filed: June 18, 2007
    Publication date: March 4, 2010
    Inventors: Angela Krackhardt, Ingrid Schuster, Dirk Busch